Key result
Lifestyle changes and triglyceride-lowering drugs manage multifactorial chylomicronemia syndrome to reduce pancreatitis and CV risk.
Why the study?
To understand the role of multifactorial chylomicronemia syndrome as a cause of severe hypertriglyceridemia, distinguish it from other causes, and provide a rational treatment approach.
MFCS is a distinct cause of severe hypertriglyceridemia that requires targeted management of secondary causes, offending drugs, and fibrate therapy to prevent pancreatitis and cardiovascular disease.
PURPOSE OF REVIEW: The aim of this review was to understand the role of multifactorial chylomicronemia syndrome (MFCS) as a cause of severe hypertriglyceridemia; to distinguish it from other causes of severe hypertriglyceridemia; and to provide a rational approach to treatment. RECENT FINDINGS: There have been advances in understanding the genetic underpinning of MFCS, and a better appreciation as to how to differentiate it from the much rarer familial chylomicronemia syndrome, in which there are substantial differences in the approach to their treatment. New approaches to triglyceride lowering will help reduce the risk of pancreatitis, the major complication of MFCS. SUMMARY: MCSF is a condition in which plasma triglyceride levels are severely elevated, usually to due exacerbation of common genetic forms of hypertriglyceridemia by secondary causes of hypertriglyceridemia and/or triglyceride-raising drugs. Triglyceride-induced pancreatitis can be prevented by markedly reducing triglyceride levels by treating secondary causes and/or eliminating of triglyceride-raising drugs, and by using triglyceride-lowering drugs, especially fibrates. MFCS also increases cardiovascular disease risk, for which lifestyle measures and drugs are required.
No takes yet. Share an insight, caveat, or question.
Alan Chait (2023) conducted a review in Multifactorial chylomicronemia syndrome. Triglyceride-lowering treatments (fibrates, lifestyle, treating secondary causes) was evaluated. Multifactorial chylomicronemia syndrome causes severe hypertriglyceridemia, increasing pancreatitis and cardiovascular risk, which can be managed via lifestyle changes and triglyceride-lowering drugs.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: